Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Hollywood and the Metaverse’s effect on pharma’s content

Translarna not approved by NICE for DMD on NHS

Amylyx ALS drug draws criticism over $158,000 price tag

Positive phase 3 results for Zealand Pharma’s glepaglutide

Low-Priced Oncology Disruptors: The Cuckoo in the PD-1/PD-L1 Nest or the Runt of the Clutch?

Enbrel

Tablets on dollar bills (treatment, addiction, aging - concept).

News/ News/ Sales and Marketing

Amgen’s Enbrel heads ICER list of unjustified US price rises

Phil Taylor AbbVie, Amgen, Biogen, Bristol-Myers Squibb, drug prices, Enbrel, ICER, Johnson & Johnson, Salix, UCB, US 0 Comment

US cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and

X

Amgen’s Enbrel heads ICER list of unjustified US price rises

https://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/

AmgenLandscape 2

Market Access/ News/ News

Amgen strikes outcomes-based payment plan for Enbrel with Abarca

Richard Staines Abarca, Amgen, Enbrel, inflammatory diseases 0 Comment

Pharmacy benefit manager Abarca has announced a US reimbursement contract with Amgen for its Enbrel (etanercept) inflammatory diseases

X

Amgen strikes outcomes-based payment plan for Enbrel with Abarca

https://pharmaphorum.com/news/amgen-strikes-outcomes-based-payment-plan-for-enbrel-with-abarca/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Supreme court throws Novartis a lifeline for Gilenya defense
Amylyx ALS drug draws criticism over $158,000 price tag
Intercept hit hard as NASH trial misses the mark
Translarna not approved by NICE for DMD on NHS
Positive phase 3 results for Zealand Pharma's glepaglutide

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com